These alterations include mutations and/or amplifications of one of the genes encoding one of the four catalytic subunits (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ).9,10 The PIK3CA alterations induce a transformed phenotype resulting in independent cell growth and therapy resistance.9,10 Although alpelisib is now only registered and approved for HR+/HER2-negative PIK3CA-mutated metastatic breast cancer, the prevalence of actionable PIK3CA mutations in various tumor types offers the potential to be used in many more patients, beyond its registration and approval label. This evidence concerns the gene ERBB2 and neoplasm.